智飞生物上半年净利亏损5.97亿元，同比由盈转亏

Core Viewpoint - The company reported a significant decline in revenue and a shift to net loss in the first half of 2025, attributed to vaccine hesitancy, fluctuating demand, and intensified competition in the industry [1] Financial Performance - The company achieved a revenue of 4.919 billion yuan in the first half of 2025, representing a year-on-year decrease of 73.06% [1] - The net profit attributable to shareholders was -599 million yuan, compared to a profit of 2.234 billion yuan in the same period last year, indicating a shift from profit to loss [1] Industry Challenges - The industry is currently under pressure due to factors such as vaccine hesitancy, fluctuating demand, and increased competition [1] - The company noted a high proportion of inventory relative to total assets, which poses a risk of further impairment if sales do not meet expectations [1] Strategic Responses - The company is negotiating with partners to adjust procurement plans to alleviate upstream supply pressure [1] - The company is optimizing promotional strategies and participating in government welfare projects to enhance public confidence in vaccines and increase vaccination willingness [1] - Efforts are being made to promote products and accelerate inventory turnover through various multidimensional approaches [1]